Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Mulissa, Zewdie ^a   Jerene, Degu ^b   Lindtjørn, Bernt ^a,c  

^a Arba Minch Hospital   (Ethiopia)

^b WHO Country Office   (Ethiopia)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGE; CD4 LYMPHOCYTE COUNT; CLINICAL CLASSIFICATION; CONTROLLED STUDY; DISEASE SEVERITY; EARLY INTERVENTION; EDUCATIONAL STATUS; ETHIOPIA; FEMALE; FOLLOW UP; HEALTH CARE AVAILABILITY; HEALTH SERVICES RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; REVIEW; RISK ASSESSMENT; RURAL AREA; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT DURATION; ARTICLE; COHORT ANALYSIS; MIDDLE AGED; SURVIVAL;

ANTI-HIV AGENTS; COHORT STUDIES; ETHIOPIA; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 78149428269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013268     Document Type: Review

References (29)

1. Posse M, Meheus F, van Asten H, van der Ven A, Baltussen R (2008) Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 13: 904-913.
2. Mugavero MJ (2008) Improving engagement in HIV care: what can we do? Top HIV Med 16: 156-161.
3. WHO/UNAIDS/UNICEF (2009) Towards Universal Access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009.
4. Assefa Y, Jerene D, Lulseged S, Ooms G, Van Damme W (2009) Rapid scale-up of antiretroviral treatment in Ethiopia: successes and system-wide effects. PLoS Med 6: e1000056.
5. FDRE (2008) Report on progress towards implementation of the UN Declaration of commitment on HIV/AIDS.
6. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
7. Jerene D, Endale A, Hailu Y, Lindtjorn B (2006) Predictors of early death in a cohort of Ethiopian patients treated with HAART. BMC Infect Dis 6: 136.
8. Jerene D, Lindtjorn B (2005) Disease Progression Among Untreated HIVInfected Patients in South Ethiopia: Implications for Patient Care. J Int AIDS Soc 7: 66.
9. Jerene D, Naess A, Lindtjorn B (2006) Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res Ther 3: 10.
10. MOH (2005) Guideline for use of Antiretroviral drugs in Ethiopia. Addis Ababa: Ministry of Health.
11. MOH/HAPCO/DACA (2003) Guidelines for use of antiretroviral drugs in Ethiopia. Addis Ababa.
12. Keruly JC, Moore RD (2007) Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 45: 1369-1374.
13. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, et al. (2009) Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 9: 290.
14. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, et al. Who starts antiretroviral therapy in Durban, South Africa? not everyone who should. AIDS 24(Suppl 1): S37-44.
15. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, et al. (2009) Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 51: 135-139.
16. Raguenaud ME, Isaakidis P, Zachariah R, Te V, Soeung S, et al. (2009) Excellent outcomes among HIV+ children on ART, but unacceptably high pre- ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatr 9: 54.
17. Thai S, Koole O, Un P, Ros S, De Munter P, et al. (2009) Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 14: 1048-1058.
18. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43: 770-776.
19. FDRE (2002) Policy on antiretroviral drugs supply and use of the Federal Democratic Republic of Ethiopia.
20. Lubega M, Nsabagasani X, Tumwesigye NM, Wabwire-Mangen F, Ekstrom AM, et al. (2009) Policy and practice, lost in transition: Reasons for high drop-out from pre-antiretroviral care in a resource-poor setting of eastern Uganda. Health Policy.
21. Brinkhof MWG, Pujades-Rodriguez M, Egger M (2009) Mortality of Patients Lost to Follow-Up in Antiretroviral Treatment Programmes in Resource- Limited Settings: Systematic Review and Meta-Analysis. PLoS ONE 4: e5790.
22. Dou Z, Zhao Y, He Y, He W, Ji G, et al. (2009) A retrospective cohort study on reduction of AIDS mortality among patients enrolled in national-free antiretroviral treatment programme in two cities in China. Chinese journal of preventive medicine 43: 1091-1095.
23. Brinkhof MWG, Boulle A, Weigel R, Messou En, Mathers C, et al. (2009) Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub- Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Med 6: e1000066.
24. Kiboneka A, Nyatia RJ, Nabiryo C, Anema A, Cooper CL, et al. (2009) Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ 338: b201.
25. Grabar S, Weiss L, Costagliola D (2006) HIV infection in older patients in the HAART era. J Antimicrob Chemother 57: 4-7.
26. Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M, et al. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
27. Santiago P, Ángeles M, Rodriguez A, Garcia M, Jose DH, et al. (2007) Progression to AIDS and Death and Response to HAART in Men and Women from a Multicenter Hospital-Based Cohort. JOURNAL OF WOMEN'S HEALTH 16(7): 1052-1061.
28. Ait-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, et al. (2009) Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis 13: 927-935.
29. Lawn SD, Harries AD, Wood R (2010) Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 5: 18-26.